BioCentury
ARTICLE | Financial News

Emulate expands series B, strikes deals

October 20, 2016 7:00 AM UTC

Organ-on-chip company Emulate Inc. (Boston, Mass.) said it added $17 million to its series B round, bringing the round's total to $45 million. Undisclosed private individuals and institutional and non-institutional funds joined the round for the new close. Emulate announced the $28 million first close in March (see BioCentury Extra, March 28).

Also on Thursday, Emulate said it partnered with the Covance Inc. contract research unit of Laboratory Corp. of America Holdings (NYSE:LH) and the Lawrence J. Ellison Institute for Transformative Medicine at the University of Southern California. Emulate and LabCorp will work to improve preclinical drug evaluation and drug development, focusing initially on Emulate's Kidney-Chip to examine drug-transporter interactions. The USC collaboration concerns organ and disease models to predict responses to cancer treatments. ...